{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'Abbreviation', 'Definition of Term', 'AC', 'Adenosquamous carcinoma', 'ADA', 'Anti-drug antibody', 'ADL', 'Activities of Daily Living', 'AE', 'Adverse event', 'AESI', 'Adverse event of special interest', 'ALT', 'Alanine aminotransferase', 'ANC', 'Absolute neutrophil count', 'AST', 'Aspartate aminotransferase', 'ATC', 'Anatomical therapeutic chemical', 'BHCG', '-human chorionic gonadotropin', 'BUN', 'Blood urea nitrogen', 'CI', 'Confidence interval', 'COVID-19', 'Coronavirus Disease 2019', 'CR', 'Complete response', 'CRF', 'Case report form (electronic or paper)', 'CSCC', 'Cutaneous squamous cell carcinoma', 'CT', 'Computed tomography', 'DOR', 'Duration of response', 'DBL', 'Database Lock', 'EC', 'Ethics Committee', 'ECG', 'Electrocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'EDC', 'Electronic data capture', 'EMA', 'European Medicines Agency', 'ENGOT', 'European Network for Gynaecological Oncological Trial', 'EORTC QLQ30', 'European Organization for Research and Treatment of Cancer Quality of Life', 'Questionnaire-Core 30', 'FAS', 'Full analysis set', 'FDA', 'Food and Drug Administration', 'FFPE', 'Formalin-fixed, paraffin-embedded', 'FIH', 'First-in-human', 'GCP', 'Good Clinical Practice', 'GOG', 'Gynecologic Oncology Group', 'Regeneron Pharmaceuticals, Inc.', 'Page 32 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Abbreviation', 'Definition of Term', 'Gy', 'Gray', 'HBV', 'Hepatitis B virus', 'HCV', 'Hepatitis C virus', 'HCG', '-human chorionic gonadotropin', 'HIV', 'Human immunodeficiency virus', 'HPV', 'Human papillomavirus', 'HR', 'Hazard ratio', 'IC', \"Investigator's choice\", 'ICF', 'Informed consent form', 'ICH', 'International Council for Harmonisation', 'IDMC', 'Independent Data Monitoring Committee', 'IHC', 'Immunohistochemistry', 'ILD', 'Interstitial lung disease', 'irAE', 'Immune-related adverse event', 'IRB', 'Institutional Review Board', 'IV', 'Intravenous(ly)', 'IVRS', 'Interactive voice response system', 'IWRS', 'Interactive web response system', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MRI', 'Magnetic resonance imaging', 'NCCN', 'National Comprehensive Cancer Network', 'NCI-CTCAE', 'National Cancer Institute-Common Terminology Criteria for Adverse Events', 'ORR', 'Objective response rate', 'os', 'Overall survival', 'PBMC', 'Peripheral blood mononuclear cells', 'PD', 'Progressive disease', 'PD-1', 'Programmed death-1', 'PD-L1', 'Programmed death ligand 1', 'PD-L2', 'Programmed death ligand 2', 'PFS', 'Progression-free survival', 'PI 3-K', 'Phosphatidylinositol 3-kinase', 'PK', 'Pharmacokinetic(s)', 'PR', 'Partial response', 'Regeneron Pharmaceuticals, Inc.', 'Page 33 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Abbreviation', 'Definition of Term', 'PT', 'Preferred term', 'Q2W', 'Every 2 weeks', 'Q3W', 'Every 3 weeks', 'QOL', 'Quality of life', 'RECIST', 'Response Evaluation Criteria in Solid Tumors', 'Regeneron', 'Regeneron Pharmaceuticals, Inc.', 'ROW', 'Rest of world', 'SAE', 'Serious adverse event', 'SAF', 'Safety analysis set', 'SAP', 'Statistical analysis plan', 'SCC', 'Squamous cell carcinoma', 'SD', 'Stable disease', 'SOC', 'System organ class', 'TCGA', 'The Cancer Genome Atlas', 'TEAE', 'Treatment-emergent adverse event', 'TSC', 'Trial Steering Committee', 'TSH', 'Thyroid-stimulating hormone', 'ULN', 'Upper limit of normal', 'US', 'United States', 'WBC', 'White blood cell', 'WOCBP', 'Women of child-bearing potential', 'Regeneron Pharmaceuticals, Inc.', 'Page 34 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}